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may reflect more effective population targeting and improved instrument 
coverage. Additional research will determine whether the two subscale structure 
of the NEI VFQ-25-R provides better interpretability of potential differences in 
patient-reported visual functioning than the NEI VFQ-25.  
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OBJECTIVES: This study aimed to assess the patient perception about brand 
name and generic drugs and to identify clusters with different preferences, and 
to evaluate the willingness to pay for a brand-name drug over a generic 
alternative. METHODS: A cross-sectional survey was conducted through self-
administered, online questionnaire. The questionnaire comprised 27 items, 
which included several attributes of pharmaceutical products like therapeutic 
efficacy, brand, price and source of information. Questionnaire also included 4 
hypothetical scenarios to ask about patients’ preferences to purchase brand-
name drugs over generic drugs and vice versa. Descriptive statistics were used to 
examine characteristics of the participants and to summarize our results. 
Preference clusters were identified, individual level utility functions were 
estimated and the willingness to pay for a brand name drug over a generic 
alternative. RESULTS: The usable response rate was 68%. The mean age of the 
respondents was approximately 29 years (range 18-68 years). Most respondents 
believed that generic drugs were less expensive (91.8%) and therapeutically 
effective (72.2%) than brand-name drugs, but only 52.2% preferred to take generic 
drugs themselves. Four clusters with distinctive individual level preferences with 
some differences in socioeconomic background were identified. About half of the 
respondents were price sensitive. Approximately 62% of the respondents were 
willing to take brand-name drugs for chronic diseases such as cardiovascular 
and respiratory diseases. 74% respondents preferred to purchase over the 
counter generic drugs for general ailments such as headache, sore throat and 
fever. Few respondents had preferences such as specific brand or to have a 
pharmacist or a physician as an information source for buying over the counter 
drugs. CONCLUSIONS: These findings provided new information on the 
consequent effects of price, efficacy, counseling, brand and other product 
characteristics on the choice by patients between branded and generic drug.  
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OBJECTIVES: Initial medication adherence, filling pharmacy scripts when first 
prescribed to begin a regimen, is an important yet understudied area. Long-term 
outcomes for chronically ill patients are dependent upon this critical early 
treatment phase. Recognizing how research findings can inform subsequent 
translation into effective clinical practices, this study summarizes the current 
literature on behavioral and psychosocial risk factors affecting initial medication 
adherence. METHODS: An international working group conducted a 
comprehensive systematic review utilizing multiple search terms for patient, 
provider or organizational factors associated with initial adherence. Following 
rigorous efforts limiting inclusion to studies targeting initial adherence versus 
broader or more ambiguous early treatment periods, we reviewed publications 
presenting primary data from 1966-2012. Eligible articles were abstracted 
documenting terminology, methodological approaches, and factors associated 
with adherence problems. We noted the frequency that unique risk factors were 
analyzed and their relative effect sizes calculated by the study authors. 
RESULTS: Only 24 publications met eligibility criteria from 865 potentially 
relevant publications. The diverse papers covered an array of study designs, 
anaytic techniques, and populations (7 countries, sample sizes 60–5.2 million), 
utilizing administrative datasets and self-reported surveys. Several articles 
modelled numerous risk factors yet others focused on single variables. The most 
prevalent factor (n=16) was specific medication or drug class (OR range  
1.50–4.87), followed by 14 papers reporting comorbodities or illness severity (ORs 
1.40–2.78); 11 articles noted medication cost effects (ORs 1.20–7.30). Less 
frequently cited were socioeconomic status, physician characteristics or 
medication beliefs, factors magnifying adherence problems up to six-times. 
CONCLUSIONS: Attention to critical influences upon adherence during the initial 
treatment course is imperative to improving outcomes. Evolving research efforts 
into associations between initial adherence and numerous risk factors can 
highlight contributions towards beneficial interventions. Multidisciplinary 
approaches, particularly those tailored to specific risks and patient preferences, 
may help reconcile potential barriers while establishing positive longitudinal 
medication behavior.  
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OBJECTIVES: The time trade-off (TTO) and the standard gamble (SG) are 
instruments that can be administered to patients in the direct elicitation of 
health utilities (HU). A previous systematic review of the literature (56 relevant 
publications, 79 study arms and 26 disease categories) indicated significant 
overall correlation in patient-elicited HU between TTO and SG. The present 
analysis further examined the correlation between TTO and SG within specific 
subgroups from the previous analysis. METHODS: Correlation between mean or 
median TTO and SG was explored by Spearman’s rank correlation test, when a 
sufficient number of study arms were available, for the following subgroups: 
incremental HU, disease, gender, age, income, education level and employment 
status. All comparisons were undertaken by sorting the mean or median HU 
values according to TTO, in increasing order by increments of 0.10. RESULTS: For 
the incremental analysis of mean TTO versus SG, significant positive correlation 
was observed when HU values were greater than 0.6 (r=0.687), 0.7 (r=0.478) and 
0.8 (r=0.525) or lower than 0.7 (r=0.564); no significant correlation was observed 
for HU values lower than 0.6 (r=0.7 with post-hoc analyses identifying the 
scarcity of studies as a plausible reason) or greater than 0.9 (r= -0.037). Overall 
mean SG was greater than overall mean TTO for all disease subgroups except 
HIV, with significant positive correlations observed in two diseases: 
cardiovascular disease (r=0.929) and ocular disease (r=0.504). Significant positive 
correlation was observed in both subgroups of females (r=0.814) and males 
(r=0.738). The series of subgroup analyses pertaining to median incremental HU 
values yielded findings similar to those in the analysis of means. CONCLUSIONS: 
The correlation between patient-reported TTO and SG outcomes was observed 
for numerous demographic and analytical subgroups. The occurrence of 
correlation may be more widespread than observed, given the limitations 
imposed by the existing study arm sample.  
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OBJECTIVES: Work disability is known to seriously impair individual quality of 
life and to cause considerable societal costs, primarily due to medical treatment 
and vocational rehabilitation. Following the WHO model of “disease - functional 
limitation - work disability”, we analyzed the longitudinal effects of perceived 
current health and functional limitations on future work disability. METHODS: In 
2007, two adult sub-samples of the Kantar Health European Healthcare Panel in 
Germany and UK were surveyed (n=4.008), and self-reports about perceived 
health status (SF-12), 24 different disease conditions and occupational status 
were collected. In 2012 the participants were re-contacted and completed a 
health status and work disability questionnaire. Careful panel management and 
quota adjustment ensured the representativeness of the samples for the 
populations in the countries. RESULTS: In 2007, 48.1% of the sample was full-
time (GER: 57.4%; UK: 38.9%) and 12.5% part-time (GER: 10.6%; UK: 14.5%) 
employed. Five years later, in 2012, 19% of the previously full- or part-time 
employed individuals were no longer employed due to health reasons. Health 
related unemployment in 2012 was highly correlated with general health status 
(gamma: 0.70; p<0.01) and functional limitations as measured by the SF-12 
subscale in 2007(=0.39; p>0.01). Of those still employed in 2012, 16.2% were 
impaired in their jobs. Most frequently they had to take breaks more often (7.5%), 
were restricted in performing typical elements of work (6.1%) or required special 
tools (2.7%). CONCLUSIONS: Future amount and nature of work disability of a 
workforce can be predicted by using conventional measures of perceived health 
and functional status. The potential use of prognostic considerations to assess 
the need for preventive and rehabilitative measures will be discussed.  
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OBJECTIVES: The PPIUS is a single-item patient-reported rating scale capturing 
degree of urgency associated with micturition and/or incontinence. We 
evaluated its measurement properties in patients with lower urinary tract 
symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). METHODS: 
Subjects enrolled in a Phase II, randomized, double-blind, 12-week study of fixed 
dose combinations of solifenacin with tamsulosin in an Oral Control 
Administration System (OCASTM) formulation TOCAS monotherapy, and placebo 
completed several disease specific patient reported outcomes and rated their 
level of urgency at every micturition and number of incontinence episode using 
the PPIUS prior to visits 2 (baseline), 3, 4, and 6 (end of study [EOS]). Six different 
scores were derived from the PPIUS including the mean, maximum, Total 
Urgency and Frequency Score (TUFS)* (defined as average sum of urgency 
episodes during a 24 hour period), number of urgency episodes, number of 
severe urgency episodes, and number of urge incontinence episodes. 
Measurement properties, including reliability, validity and responsiveness, were 
assessed. RESULTS: 1,010 males (mean age: 66) were enrolled. Intra class 
correlations (test-retest reliability) exceeded 0.70 for all scores. All PPIUS scores 
at Visit 2 and EOS were significantly (p<0.001) different for those above/below the 
median on International Prostate Symptom Score (IPSS) storage scores, but TUFS 
and number of urgency episodes had highest partial eta-squared values 
indicating these scores demonstrated the greatest ability to discriminate 
between groups differing in baseline severity (known groups validity). Three 
PPIUS scores (maximum, TUFS and urgency episodes) showed notably higher 
